The guidance documents advance the transition to eSTAR, an electronic template the FDA is adopting to meet legislative requirements.
FDA details switch to electronic filings for 510(k), de novo submissions Read More »
Kashiv Biosciences LLC today announced that they have entered into an exclusive licensing agreement for ADL018 (also called AVT23), a proposed biosimilar to Xolair® (omalizumab), which is in clinical development.
Anixa Biosciences, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 11,786,489, which broadens protection of Anixa’s novel ovarian cancer vaccine technology.
Ichnos Sciences Inc. today announced the promotion of Dean Thomas to the position of General Counsel, effective immediately.
ICHNOS SCIENCES PROMOTES DEAN THOMAS TO GENERAL COUNSEL Read More »
ProciseDx Inc. announces that it has been granted de novo FDA clearance for the therapeutic drug monitoring (TDM).
Lokavant , the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co. Ltd. to expand its AI-optimized platform across the Asia-Pacific (APAC) region.
Cybin Inc. today announced the completion of dosing of the final cohort in its Phase 2 study of CYB003, a proprietary deuterated psilocybin analog program in development for the potential treatment of major depressive disorder (“MDD”).
Capsida Biotherapeutics Inc. (“Capsida”) and Kate Therapeutics (“KateTx”) today announced a strategic partnership to leverage Capsida’s expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx’s initial internal portfolio of muscle and heart disease programs.
Las experiencias místicas y religiosas han sido un componente intrínseco de la historia de la humanidad desde tiempos inmemoriales. Muchos individuos afirman haber tenido encuentros con lo divino, trascendiendo la realidad cotidiana. Aunque estas experiencias a menudo se han interpreta …
El origen antropológico de las experiencias místicas y religiosas Read More »
Sphere Fluidics announced the Cyto-Mine® platform has been selected by FairJourney Biologics, a world leading end-to-end antibody partner, providing integrated services across antibody discovery, engineering, and production, to expand its cell line development capabilities.
